If your doctor thinks you have non-small-cell lung cancer (NSCLC), they will usually look for a change (they may call it a mutation) in a gene called the EGFR gene. Normally, EGFR helps healthy cells ...
Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 ...
A man with lung cancer shares how learning about his EGFR exon 20 insertion mutation soon after being diagnosed has allowed him to be aggressive when pursuing a cancer treatment tailored to his rare ...
New treatments may stall lung cancer progression in patients with EGFR exon 20 insertion mutations. After spending a warm spring day in 2022 pulling weeds and planting perennials, Renata Muller, 66, ...
Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone ...
There are promising developments in the pipeline for EGFR exon 20 insertion–positive non–small cell lung cancer (NSCLC), and groups like The Exon 20 Group can help ensure patients are getting access ...
Joshua Sabari, MD, assistant professor of medicine, Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York, New York, discusses topics involving next generation sequencing (NGS) to ...
Phase 3 WU-KONG28 trial met its primary endpoint, showing that once-daily oral sunvozertinib significantly improved progression-free survival over platinum-based doublet chemotherapy in first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results